However, in MS, the trial had to be aborted as patients treated with Atacicept experienced increased relapse frequency compared to placebo (23), suggesting that some BAFF/APRIL dependent B cell subsets may have beneficial effects on MS pathology. Here, TNFSF13B is linked to myeloid sarcoma.